✦ LIBER ✦

S100A1: A Multifaceted Therapeutic Target in Cardiovascular Disease

✍ Scribed by David Rohde; Julia Ritterhoff; Mirko Voelkers; Hugo A. Katus; Thomas G. Parker; Patrick Most

Book ID: 107639536
Publisher: Springer US
Year: 2010
Tongue: English
Weight: 680 KB
Volume: 3
Category: Article
ISSN: 1937-5387
DOI: 10.1007/s12265-010-9211-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Parasympathetic nervous system: A new th

Parasympathetic nervous system: A new therapeutic target in cardiovascular disease?

✍ Ding-Feng Su 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

PPAR: a therapeutic target in Parkinson’

PPAR: a therapeutic target in Parkinson’s disease

✍ Rajnish K. Chaturvedi; M. Flint Beal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB

Soluble epoxide hydrolase as a therapeut

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

✍ Imig, John D.; Hammock, Bruce D. 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 477 KB

Vascular inflammation as a therapeutic t

Vascular inflammation as a therapeutic target for prevention of cardiovascular disease

✍ Luther T. Clark 📂 Article 📅 2002 🏛 Current Science Inc. 🌐 English ⚖ 314 KB

LRRK2 as a therapeutic target in Parkins

LRRK2 as a therapeutic target in Parkinson’s disease

✍ E. K. Tan; A. H. Schapira 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cdk5, a therapeutic target for Alzheimer

Cdk5, a therapeutic target for Alzheimer's disease?

✍ Li-Huei Tsai; Ming-Sum Lee; Jonathan Cruz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Alzheimer's disease (AD) represents the leading cause for senile dementia affecting more than 4 million people worldwide. AD patients display a triad of pathological features including brain atrophy caused by neuronal loss, h-amyloid plaque and neurofibrillary tangles. We previously show that Cyclin